Company: NUTR
Filing Date: 2025-04-14
Form Type: S-1/A
Source: 0001641172-25-004581
Chunk: 174

Company: NUSATRIP Inc
Filing Date: 2025-04-14
Form: S-1/A
Chunk 174
---
 to the extent that it is not fully reflected in the financial statements.

NOTE 17 — SUBSEQUENT EVENTS

In accordance with ASC Topic 855, “ Subsequent Events”, which establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued, the Company has evaluated all events or transactions that occurred after December 31, 2024, up through March 18, 2025, the Company issued the carve-out combined and consolidated financial statements.

On October 18, 2024, we entered into
a securities purchase agreement with the Selling Stockholders. Pursuant to securities purchase agreement, on October 18, 2024, we will
issue the convertible notes (the “Convertible Notes”) to the Selling Stockholders with an aggregate principal amount
of $1,600,002 (the “Convertible Notes Offering”). Pursuant to the amendments to the securities purchase agreement for Convertible
Notes dated November 13, 2024, entered by the Company and the investors, the Convertible Notes shall automatically convert into shares
of our common stock upon the effectiveness of the registration statement at the conversion price of $1.50 per share. We are obligated
to pay interest to the Selling Stockholders on the outstanding principal amount at the rate of 6.0% per annum. The Convertible Notes
and the interests shall be converted into shares of common stock of the Company at a conversion price of $1.50 per share by the six months
anniversary of the issuance date or the consummation of our IPO, whichever earlier. The Convertible Notes were converted into an aggregate
of 1,066,668 shares of Common Stock and issued to the investors, and the three private placements were completed on February 10, 2025.

| F-27 |

<div align='center'>NUSATRIP INCORPORATED

3,750,000 SHARES OF COMMON STOCK

PROSPECTUS

[ ], 2025</div>

No dealer, salesperson or any other person is authorized to give any information or make any representations in connection with this Offering other than those contained in this prospectus and, if given or made, the information or representations must not be relied upon as having been authorized by us. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any security other than the securities offered by this prospectus, or an offer to sell or a solicitation of an offer to buy